Outcomes
|
Balanced crystalloids
|
0.9% Saline
|
Risk ratio/standard mean difference (95% CI)
|
---|
In-hospital mortality
|
Events/total
|
Events/total
|
Fixed models
|
Random models
|
---|
Waters et al. [20]
|
1/33
|
1/33
|
1.00 [0.07, 15.33]
|
1.00 [0.07, 15.33]
|
Takil et al. [21]
|
0/15
|
0/15
|
Not estimable
|
Not estimable
|
Van Zyl et al. [22]
|
0/27
|
0/27
|
Not estimable
|
Not estimable
|
Young et al. [23]
|
3/22
|
4/24
|
0.82 [0.21, 3.25]
|
0.82 [0.21, 3.25]
|
Young et al. [9]
|
87/1152
|
95/1110
|
0.88 [0.67, 1.17]
|
0.88 [0.67, 1.17]
|
Verma et al. [24]
|
5/33
|
2/34
|
2.58 [0.54, 12.36]
|
2.58 [0.54, 12.36]
|
Semler et al. [25]
|
72/520
|
68/454
|
0.92 [0.68, 1.26]
|
0.92 [0.68, 1.26]
|
Semler et al. [10]
|
818/7942
|
875/7860
|
0.93 [0.85, 1.01]
|
0.93 [0.85, 1.01]
|
Summary
|
986/9744
|
1045/9557
|
0.92 [0.85, 1.00]
|
0.92 [0.85, 1.00]
|
Fixed model heterogeneity: χ2 = 1.78, df = 5 (p = 0.88); I2 = 0%; test for overall effect: Z = 1.88 (p = 0.06)
|
Random model heterogeneity: τ2 = 0.00; χ2 = 1.78, df = 5 (p = 0.88); I2 = 0%; test for overall effect: Z = 1.89 (p = 0.06)
|
Outcomes
|
Balanced crystalloids
|
0.9% Saline
|
Risk ratio/standard mean difference (95% CI)
|
---|
30-day mortality
|
Events/total
|
Events/total
|
Fixed models
|
Random models
|
---|
Young et al. [23]
|
3/22
|
4/24
|
0.82 [0.21, 3.25]
|
0.82 [0.21, 3.25]
|
Semler et al. [25]
|
72/520
|
68/454
|
0.92 [0.68, 1.26]
|
0.92 [0.68, 1.26]
|
Semler et al. [10]
|
818/7942
|
875/7860
|
0.93 [0.85, 1.01]
|
0.93 [0.85, 1.01]
|
Summary
|
893/8484
|
947/8338
|
0.92 [0.85, 1.01]
|
0.92 [0.85, 1.01]
|
Fixed model heterogeneity: χ2 = 0.03, df = 2 (p = 0.98); I2 = 0%; test for overall effect: Z = 1.78 (p = 0.08)
|
Random model heterogeneity: τ2 = 0.00; χ2 = 0.03, df = 2 (p = 0.98); I2 = 0%; test for overall effect: Z = 1.78 (p = 0.08)
|
Outcomes
|
Balanced crystalloids
|
0.9% Saline
|
Risk ratio/standard mean difference (95% CI)
|
---|
60-day mortality
|
Events/total
|
Events/total
|
Fixed models
|
Random models
|
---|
Semler et al. [25]
|
87/520
|
83/454
|
0.92 [0.70, 1.20]
|
0.92 [0.70, 1.20]
|
Semler et al. [10]
|
928/7942
|
975/7860
|
0.94 [0.87, 1.02]
|
0.94 [0.87, 1.02]
|
Summary
|
1015/8462
|
1058/8314
|
0.94 [0.87, 1.02]
|
0.94 [0.87, 1.02]
|
Fixed model heterogeneity: heterogeneity: χ2 = 0.04, df = 1 (p = 0.84); I2 = 0%; test for overall effect: Z = 1.51 (p = 0.13)
|
Random model heterogeneity: τ2 = 0.00; χ2 = 0.04, df = 1 (p = 0.84); I2 = 0%; test for overall effect: Z = 1.52 (p = 0.13)
|
Outcomes
|
Balanced crystalloids
|
0.9% Saline
|
Risk ratio/standard mean difference (95% CI)
|
---|
Development of stage 2 or higher AKI
|
Events/total
|
Events/total
|
Fixed models
|
Random models
|
---|
Waters et al. [20]
|
4/33
|
5/33
|
0.80 [0.24, 2.72]
|
0.80 [0.24, 2.72]
|
Young et al. [23]
|
3/22
|
6/24
|
0.55 [0.15, 1.92]
|
0.55 [0.15, 1.92]
|
Young et al. [9]
|
105/1067
|
104/1025
|
0.97 [0.75, 1.25]
|
0.97 [0.75, 1.25]
|
Verma et al. [24]
|
1/33
|
3/34
|
0.34 [0.04, 3.14]
|
0.34 [0.04, 3.14]
|
Semler et al. [25]
|
97/520
|
87/454
|
0.97 [0.75, 1.26]
|
0.97 [0.75, 1.26]
|
Semler et al. [10]
|
807/7558
|
858/7458
|
0.93 [0.85, 1.02]
|
0.93 [0.85, 1.02]
|
Summary
|
1017/9233
|
1063/9028
|
0.93 [0.86, 1.01]
|
0.93 [0.86, 1.01]
|
Fixed model heterogeneity: χ2 = 1.74, df = 5 (p = 0.88); I2 = 0%; test for overall effect: Z = 1.71 (p = 0.09)
|
Random model heterogeneity: τ2 = 0.00; χ2 = 1.74, df = 5 (p = 0.88); I2 = 0%; test for overall effect: Z = 1.69 (p = 0.09)
|
Outcomes
|
Balanced crystalloids
|
0.9% Saline
|
Risk ratio/standard mean difference (95% CI)
|
---|
New RRT use
|
Events/total
|
Events/total
|
Fixed models
|
Random models
|
---|
Takil et al. [21]
|
0/15
|
0/15
|
Not estimable
|
Not estimable
|
Young et al. [9]
|
38/1152
|
38/1110
|
0.96 [0.62, 1.50]
|
0.96 [0.62, 1.50]
|
Verma et al. [24]
|
5/33
|
3/34
|
1.72 [0.45, 6.62]
|
1.72 [0.45, 6.62]
|
Semler et al. [25]
|
24/520
|
14/454
|
1.50 [0.78, 2.86]
|
1.50 [0.78, 2.86]
|
Semler et al. [10]
|
189/7588
|
220/7458
|
0.84 [0.70, 1.02]
|
0.84 [0.70, 1.02]
|
Summary
|
256/9308
|
275/9071
|
0.91 [0.77, 1.07]
|
0.95 [0.75, 1.21]
|
Fixed model heterogeneity: χ2 = 3.77, df = 3 (p = 0.29); I2 = 20%; test for overall effect: Z = 1.16 (= 0.24)
|
Random model heterogeneity: τ2 = 0.01; χ2 = 3.77, df = 3 (p = 0.29); I2 = 20%; test for overall effect: Z = 0.38 (p = 0.70)
|
Outcomes
|
Balanced crystalloids
|
0.9% Saline
|
Risk ratio/standard mean difference (95% CI)
|
---|
RRT-free days
|
Mean ± SD, No.
|
Mean ± SD, No.
|
Fixed models
|
Random models
|
---|
Semler et al. [25]
|
24.9 ± 9.7, 520
|
23.7 ± 10, 520
|
0.12 [− 0.00, 0.25]
|
0.12 [− 0.00, 0.25]
|
Semler et al. [10]
|
25.6 ± 8.6, 7942
|
24.8 ± 8.9, 7860
|
0.09 [0.06, 0.12]
|
0.09 [0.06, 0.12]
|
Summary
|
0.09 [0.06, 0.12]
|
0.09 [0.06, 0.12]
|
Fixed model heterogeneity: χ2 = 0.38, df = 1 (p = 0.54); I2 = 0%, test for overall effect: Z = 6.02 (p < 0.00001)
|
Random model heterogeneity: τ2 = 0.00; χ2 = 0.21, df = 1 (p = 0.65); I2 = 0%; test for overall effect: Z = 6.03 (p < 0.00001)
|
- CI confident interval, AKI acute kidney injury, RRT renal replacement therapy, SD standard difference, SMD standard mean difference